Mark A. Lemmon, PhD, FRS, Alfred Gilman Professor of Pharmacology, professor of molecular biophysics and biochemistry, and co-director of the Cancer Biology Institute, has been appointed deputy director of Yale Cancer Center, effective February 1. Lemmon joined Yale Cancer Center in 2015 to bring the concept of the Cancer Biology Institute on Yale West Campus to reality.
He has assembled a team of basic science faculty in the institute who are all members of cancer center research programs and are developing an exciting environment for interdisciplinary cancer research. Lemmon’s efforts to enhance interactions among basic, translational, population, and clinical investigators across the Cancer Center community in his former role as associate cancer center director for basic science have strengthened research collaborations. These interactions will continue to flourish through his new leadership position as Deputy Director.
Lemmon is a graduate of Oxford University and earned his PhD from Yale University. His laboratory’s research focuses on understanding the signaling networks controlled by cancer-causing receptor tyrosine kinases using cellular, biochemical, and structural approaches. In 2016, he was elected as a Fellow of the Royal Society, the United Kingdom’s national science academy, and in 2019, Lemmon received the Yale Cancer Center Research Prize for Basic Science in recognition of his paper in Cell, “EGF Receptor Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics.”